
“Roche’s Latest EMBARK Findings: Elevidys Proves Powerful for Duchenne Muscular Dystrophy Patients on the Move!”
Roche Announces Positive Results from Year Two of EMBARK Trial A Game-Changer in the Treatment of Duchenne Muscular Dystrophy Basel, 27 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from year two of the EMBARK trial, a global, randomised, double-blind phase III study of Elevidys™ (delandistrogene moxeparvovec), the first…